TAS 114

Drug Profile

TAS 114

Alternative Names: TAS-114

Latest Information Update: 05 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taiho Pharmaceutical
  • Developer National Cancer Center Hospital East; Taiho Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action Dihydropyrimidine dehydrogenase inhibitors; DUTP pyrophosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Non-small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 19 Sep 2018 Taiho Pharmaceutical terminates a phase II trial in Gastric cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease, Recurrent) in Japan (PO) (UMIN000028329)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in Italy (PO)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top